Interdisciplinary NexGen TB research Advancement Center (IN-TRAC)
跨学科 NexGen 结核病研究推进中心 (IN-TRAC)
基本信息
- 批准号:10588203
- 负责人:
- 金额:$ 115.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-10 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAnimal ModelAnimalsBiomedical ResearchChestCitiesClinicClinicalClinical ManagementClinical ResearchClinical ServicesCommunicable DiseasesCommunicationCommunitiesComplementComprehensionConfocal MicroscopyCountryCytometryDevelopmentDisciplineEducational CurriculumFundingFunding AgencyGrantHealthHealth ProfessionalHospitalsIACUCImageIndividualIndustryInpatientsInterdisciplinary StudyInternshipsKnowledgeLeadershipLearningMechanicsMexicoMissionMusNational Institute of Allergy and Infectious DiseaseOutpatientsPET/CT scanParticipantPatient CarePreventionProceduresProtocols documentationResearchResearch InstituteResearch PersonnelResourcesRisk AssessmentRodentScienceScientistSiteTexasTrainingTraining ProgramsTuberculosisUnited States National Institutes of HealthUniversitiesWorkWritingbiocontainment facilitycareer developmentcellular imagingcohortcommercializationexperienceexternshiplive cell imagingmetropolitanmultidisciplinarynext generationnonhuman primateorganizational structurepeerpoint of carepreventprogramsprospectivesingle-cell RNA sequencingskillssuccesstoolwhole body imaging
项目摘要
TEXAS BIOMED IN-TRAC OVERALL ABSTRACT
The Interdisciplinary NexGen TB Research Advancement Center (IN-TRAC) at Texas Biomedical Research
Institute (Texas Biomed) will attract the next generation of diverse researchers to the tuberculosis (TB) research
field, and develop them into independent researchers with multi-disciplinary skills and real-world experience of
clinical TB. The product of IN-TRAC will be researchers that choose to work on some of the most challenging
and relevant translational problems in TB, and that work across academic disciplines and within a framework of
highly collaborative research. This will be achieved through 6 interrelated Cores. Administrative Core: The
central hub of IN-TRAC management and oversight, with responsibility for administrative and scientific
leadership; coordinating communication between Cores, researchers and NIH/NIAID Program staff and
providing an organizational structure to optimize multidisciplinary collaborations and interactions between the
Cores and among a diverse cohort of IN-TRAC participants. Development Core: Oversight of all career
development programming and courses, tailoring the research and clinical experiences, both intern and
externships, to each individual IN-TRAC participant, and management of the IN-TRAC pilot grant program.
Biosafety & Biocontainment Core: Extending the required biosafety training to a personalized curriculum
including theoretical and hands-on biocontainment training, understanding the mechanical and regulatory
requirements of a BSL3/ABSL3, coaching on how to develop biosafety protocols, and working through risk
assessments from the perspective of a Biosafety Officer. Research Imaging Core: Providing theoretical and
hands-on training from single cell imaging (confocal microscopy, cytometry, live cell imaging, single cell RNAseq)
through to whole body imaging in mice (IVIS) and Non-human primates (NHP) (PET/CT) within large, fully
outfitted BSL3/ABSL3 facilities. Animal Model Core: Implementing a training program to introduce all IN-TRAC
participants to the regulatory requirements for working with rodents and NHPs, how to develop a robust
experimental protocol, how to write an IACUC protocol, and hands-on animal handling and experimental
procedures. Clinical Research & Patient Care Core: Introducing IN-TRAC participants to TB patient care at
the only free-standing TB hospital in the US (Texas Center of Infectious Diseases) that manages some of the
most challenging cases of TB nationally. Partnering with this will be a clinical research experience at the US-
Mexico border, to experience TB studies in under-served and under-resourced communities.
德克萨斯州生物术中的整体抽象
德克萨斯生物医学研究的跨学科Nexgen TB研究进步中心(IN-TRAC)
研究所(得克萨斯州生物元素)将吸引下一代多元化研究人员进行结核病研究(TB)研究
领域,并将其发展为具有多学科技能和现实世界经验的独立研究人员
临床结核TRAC的产物将是研究人员,他们选择从事一些最具挑战性的工作
以及结核病中的相关翻译问题,以及在学科跨学科以及在一个框架内的工作
高度协作研究。这将通过6个相互关联的内核来实现。行政核心:
贸易管理和监督的中央枢纽,负责行政和科学
领导;协调核心,研究人员与NIH/NIAID计划人员之间的沟通以及
提供组织结构,以优化多学科的合作以及
核心以及各种各样的搜索参与者。发展核心:对所有职业的监督
开发计划和课程,量身定制研究和临床经验
实习,对每个个人进水参与者以及贸易中试点赠款计划的管理。
生物安全与生物内在核心核心:将所需的生物安全培训扩展到个性化课程
包括理论和动手生物内在培训,了解机械和调节性
BSL3/absl3的要求,有关如何制定生物安全协议的指导以及通过风险进行的
从生物安全官员的角度进行评估。研究成像核心:提供理论和
单细胞成像(共聚焦显微镜,细胞术,活细胞成像,单细胞RNASEQ)的动手训练
通过小鼠(IVI)和非人类灵长类动物(NHP)(PET/CT)的全身成像到全身成像
装备的BSL3/ABSL3设施。动物模型核心:实施培训计划以介绍所有轨道
参与者满足与啮齿动物和NHP合作的监管要求,如何开发强大的
实验方案,如何编写IACUC协议以及动物动物处理和实验
程序。临床研究与患者护理核心:将Trac In-Trac参与者引入结核病患者护理
美国唯一的独立结核病医院(得克萨斯州传染病中心)管理了一些
全国结核病的最具挑战性案例。与此合作将是美国的临床研究经验
墨西哥边境,在服务不足和资源不足的社区中进行结核病研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Larry S. Schlesinger其他文献
Identifying Mycobacterium tuberculosis virulence determinants - new technologies for a difficult problem.
识别结核分枝杆菌毒力决定因素——解决难题的新技术。
- DOI:
- 发表时间:
2000 - 期刊:
- 影响因子:15.9
- 作者:
Lucy E. Desjardin;Larry S. Schlesinger - 通讯作者:
Larry S. Schlesinger
Antibody-independent classical complement pathway activation by wildtype and LPS O-antigen mutant <em>Francisella tularensis</em> strains
- DOI:
10.1016/j.molimm.2010.05.146 - 发表时间:
2010-08-01 - 期刊:
- 影响因子:
- 作者:
Corey D. Clay;John S. Gunn;Larry S. Schlesinger - 通讯作者:
Larry S. Schlesinger
Larry S. Schlesinger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Larry S. Schlesinger', 18)}}的其他基金
Interdisciplinary NexGen TB research Advancement Center (IN-TRAC)
跨学科 NexGen 结核病研究推进中心 (IN-TRAC)
- 批准号:
10431465 - 财政年份:2022
- 资助金额:
$ 115.01万 - 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器
- 批准号:
10450960 - 财政年份:2020
- 资助金额:
$ 115.01万 - 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器
- 批准号:
10457308 - 财政年份:2019
- 资助金额:
$ 115.01万 - 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection- Diversity Supplement
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器 - Diversity Supplement
- 批准号:
10116937 - 财政年份:2019
- 资助金额:
$ 115.01万 - 项目类别:
Expansion of Marmoset Breeding Facilities to Meet Increasing Research Demands
扩建狨猴饲养设施以满足不断增长的研究需求
- 批准号:
9933536 - 财政年份:2019
- 资助金额:
$ 115.01万 - 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器
- 批准号:
10215474 - 财政年份:2019
- 资助金额:
$ 115.01万 - 项目类别:
相似国自然基金
髋关节撞击综合征过度运动及机械刺激动物模型建立与相关致病机制研究
- 批准号:82372496
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
利用碱基编辑器治疗肥厚型心肌病的动物模型研究
- 批准号:82300396
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
利用小型猪模型评价动脉粥样硬化易感基因的作用
- 批准号:32370568
- 批准年份:2023
- 资助金额:50.00 万元
- 项目类别:面上项目
丁苯酞通过调节细胞异常自噬和凋亡来延缓脊髓性肌萎缩症动物模型脊髓运动神经元的丢失
- 批准号:82360332
- 批准年份:2023
- 资助金额:31.00 万元
- 项目类别:地区科学基金项目
APOBEC3A驱动膀胱癌发生发展的动物模型及其机制研究
- 批准号:82303057
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
相似海外基金
Effects of tACS on alcohol-induced cognitive and neurochemical deficits
tACS 对酒精引起的认知和神经化学缺陷的影响
- 批准号:
10825849 - 财政年份:2024
- 资助金额:
$ 115.01万 - 项目类别:
Impact of tissue resident memory T cells on the neuro-immune pathophysiology of anterior eye disease
组织驻留记忆 T 细胞对前眼疾病神经免疫病理生理学的影响
- 批准号:
10556857 - 财政年份:2023
- 资助金额:
$ 115.01万 - 项目类别:
Endothelial Cell Reprogramming in Familial Intracranial Aneurysm
家族性颅内动脉瘤的内皮细胞重编程
- 批准号:
10595404 - 财政年份:2023
- 资助金额:
$ 115.01万 - 项目类别:
Dravet Syndrome Anti-Epileptic Control by Targeting GIRK Channels
通过针对 GIRK 通道进行 Dravet 综合征抗癫痫控制
- 批准号:
10638439 - 财政年份:2023
- 资助金额:
$ 115.01万 - 项目类别: